Eight study results findings on COVID-19 vaccines reported by Becker's Hospital Review in June:
- Mixing brands of COVID-19 vaccines can create strong protection against the virus, according to early results of a British study. Volunteers in a clinical trial showed high levels of antibodies and immune cells after getting one dose of Pfizer's COVID-19 and one dose of AstraZeneca's.
- The immune response triggered by mRNA vaccines made by Pfizer and Moderna may last for years, according to research published in Nature.
- Skin reactions to the vaccines made by Pfizer and Moderna are rare and unlikely to recur when receiving the second dose, according to a study published in JAMA Dermatology.
- CureVac's COVID-19 vaccine was just 47 percent effective in clinical trials, an interim trial analysis found. The trial enrolled about 40,000 people in Latin America and Europe, where at least 13 coronavirus variants were prevalent.
- Pfizer and AstraZeneca's vaccines are both highly effective in preventing hospitalization from the delta coronavirus variant, according to a study published by Public Health England. Two doses of Pfizer's vaccine were 96 percent effective in preventing hospitalization from the delta variant, and two doses of AstraZeneca's vaccine were 92 percent effective.
- Novavax's vaccine was 100 percent effective at protecting against moderate to severe COVID-19 and 90.4 effective overall in a phase 3 trial of 29,960 people.
- AstraZeneca's vaccine poses a slight risk of bleeding problems for recipients, according to a study published in Nature Medicine. In the study, the vaccine was linked to a slightly increased risk of immune thrombocytopenic purpura, a disorder that can cause serious bleeding. The study estimated the risk was 1.13 cases per 100,000 people receiving their first AstraZeneca vaccine dose, up to 27 days after vaccination.
- Johnson & Johnson's vaccine is effective against several coronavirus variants, according to a study published in Nature. The study found the vaccine activated responses against the original coronavirus strain, as well as the alpha, beta, gamma and epsilon variants.